|
[1]Committee of experts on antiviral therapy for special patients with chronic hepatitis B.Expert consensus on antiviral therapy for special patients with chronic hepatitis B:an update in 2015[J].J Clin Hepatol,2015,31(8):1185-1192.(in Chinese)慢性乙型肝炎特殊患者抗病毒治疗专家委员会.慢性乙型肝炎特殊患者抗病毒治疗专家共识:2015年更新[J].临床肝胆病杂志,2015,31(8):1185-1192.
|
|
[2]Committee for the management of hepatitis B virus infection in pregnancy.Expert consensus on the management of hepatitis B virus infection in pregnancy[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition,2014,8(1):104-107.(in Chinese)乙型肝炎病毒感染女性生育管理委员会.乙型肝炎病毒感染女性生育管理专家共识[J/CD].中华实验和临床感染病杂志:电子版,2014,8(1):104-107.
|
|
[3]Obstetrics Subgroup,Chinese Society of Obstetrics and Gynecology,Chinese Medical Association.Clinical guidelines for the prevention of mother-to-child transmission of hepatitis B virus[J].Chin J Obstetr Gynecol,2013,48(2):151-154.(in Chinese)中华医学会妇产科学分会产科学组.乙型肝炎病毒母婴传播预防临床指南(第1版)[J].中华妇产科杂志,2013,48(2):151-154.
|
|
[4] VISVANATHAN K,DUSHEIKO G,GILES M,et al.Managing HBV in pregnancy.Prevention,prophylaxis,treatment and follow-up:position paper produced by Australian,UK and New Zealand key opinion leaders[J].Gut,2016,65(2):340-350.
|
|
[5]YANG YB,LI XM,SHI ZJ,et al.Pregnant woman with fulminant hepatic failure caused by hepatitis B virus infection:a case report[J].World J Gastroenterol,2004,10(15):2305-2306.
|
|
[6]SAFIR A,LEVY A,SIKULER E,et al.Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome[J].Liver Int,2010,30(5):765-770.
|
|
[7]TSE KY,HO LF,LAO T.The impact of maternal HBs Ag carrier status on pregnancy outcomes:a case-control study[J].J Hepatol,2005,43(5):771-775.
|
|
[8] VIGANA,MORA S,GIACOMET V,et al.In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers[J].Antivir Ther,2011,16(8):1259-1266.
|
|
[9] GIBB DM,KIZITO H,RUSSELL EC,et al.Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial[J].PLo S Med,2012,9(5):e1001217.
|
|
[10]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.
|
|
[11] LEE SD,LO KJ,TSAI YT,et al.Role of caesarean section in prevention of mother-infant transmission of hepatitis B virus[J].Lancet,1988,2(8615):833-834.
|
|
[12]PAN CQ,ZOU HB,CHEN Y,et al.Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants[J].Clin Gastroenterol Hepatol,2013,11(10):1349-1355.
|
|
[13]WANG J,ZHU Q,ZHANG X.Effect of delivery mode on maternalinfant transmission of hepatitis B virus by immunoprophylaxis[J].Chin Med J(Engl),2002,115(10):1510-1512.
|
|
[14]SUN DF,CHEN WQ.Analysis of correlation factors of intrauterine interruption failure for HBV infected pregnant women using HBIGduring the last trimester of pregnancy[J].Matern Child Health Care China,2010,25(14):1923-1925.(in Chinese)孙待飞,陈卫群.孕晚期HBIG阻断HBV宫内感染失败的相关因素研究[J].中国妇幼保健,2010,25(14):1923-1925.
|
|
[15]YI W,PAN CQ,HAO J,et al.Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers[J].J Hepatol,2014,60(3):523-529.
|
|
[16]HUI L,THE S,Mc CARTHY EA,et al.Emerging issues in invasive prenatal diagnosis:safety and competency in the post-NIPT era[J].Aust N Z J Obstet Gynaecol,2015,55(6):541-546.
|
|
[17] DAVIES G,WILSON RD,DESILETS V,et al.Amniocentesis and women with hepatitis B,hepatitis C,or human immunodeficiency virus[J].J Obstet Gynaecol Can,2003,25(2):145-148,149-152.
|
|
[18]GILES ML,GRACE R,TAI A,et al.Prevention of mother-tochild transmission of hepatitis B virus(HBV)during pregnancy and the puerperium:current standards of care[J].Aust N Z J Obstet Gynaecol,2013,53(3):231-235.
|
|
[19] SHI Z,YANG Y,MA L,et al.Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus:a systematic review and meta-analysis[J].Obstet Gynecol,2010,116(1):147-159.
|
|
[20]HAN L,ZHANG HW,XIE JX,et al.A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus[J].World J Gastroenterol,2011,17(38):4321-433.
|
|
[21]HAN GR,CAO MK,ZHAO W,et al.A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J].JHepatol,2011,55(6):1215-1221.
|
|
[22] JIANG Q,YU M.A retrospective study of the comparisons between telbivudine and lamvudine on the efficacy and safety in antiviral treatment of hepatitis b virus during pregnancy[R].47th Annual Meeting of the European Association for the Study of the Liver,18-22 April 2012.JHepatol,2012,56:s205.
|
|
[23]PAN CQ,HAN GR,JIANG HX,et al.Telbivudine prevents vertical transmission from HBe Ag-positive women with chronic hepatitis B[J].Clin Gastroenterol Hepatol,2012,10(5):520-526.
|
|
[24]GREENUP AJ,TAN PK,NGUYEN V,et al.Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus[J].J Hepatol,2014,61(3):502-507.
|
|
[25] CHEN HL,LEE CN,CHANG CH,et al.Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus[J].Hepatology,2015,62(2):375-386.
|
|
[26] SINGH AE,PLITT SS,OSIOWY C,et al.Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants[J].J Viral Hepat,2011,18(7):468-473.
|
|
[27]ZHANG SL,YUE YF,BAI GQ,et al.Mechanism of intrauterine infection of hepatitis B virus[J].World J Gastroenterol,2004,10(3):437-438.
|
|
[28]SU GG,PAN KH,ZHAO NF,et al.Efficacy and safety of lamivudine treatment forchronic hepatitis B in pregnancy[J].World JGastroenterol,2004,10(6):910-912.
|
|
[29]LI XM,YANG YB,HOU HY,et al.Interruption of HBV intrauterine transmission:a clinical study[J].World J Gastroenterol,2003,9(7):1501-1503.
|
|
[30] XU WM,CUI YT,WANG L,et al.Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection:a multicentre,randomized,double-blind,placebo-controlled study[J].J Viral Hepat,2009,16(2):94-103.
|
|
[31]van ZONNEVELD M,van NUNEN AB,NIESTERS HG,et al.Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection[J].J Viral Hepat,2003,10(4):294-297.
|
|
[32]van NUNEN AB,de MAN RA,HEIJTINK RA,et al.Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients[J].J Hepatol,2000,32(6):1040-1041.
|
|
[33] HAN GR,JIANG H,ZHAO W,et al.Lamivudine use in the 2nd or 3rd trimester of pregnancy has similar efficacy in preventing vertical transmission(VT)of chronic hepatitis B(CHB)in highly viremic mothers[R].62nd Annual Meeting of the American Association for the Study of Liver Diseases,4-8 November 2011,San Francisco,USA;Oral 236.Hepatology,2011,54:122a.
|
|
[34]NGUYEN V,TAN PK,GREENUP AJ,et al.Anti-viral therapy for prevention of perinatal HBV transmission:extending therapy beyond birth does not protect against post-partum flare[J].Aliment Pharmacol Ther,2014,39(10):1225-1234.
|
|
[35]Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.
|
|
[36]GILES M,VISVANATHAN K,LEWIN S,et al.Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B[J].Gut,2015,64(11):1810-1815.
|
|
[37] MOODLEY J,MOODLEY D,PILLAY K,et al.Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring[J].J Infect Dis,1998,178(5):1327-1333.
|
|
[38] SHAPIRO RL,HOLLAND DT,CAPPARELLI E,et al.Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment[J].J Infect Dis,2005,192(5):720-727.
|
|
[39] BENABOUD S,PRUVOST A,COFFIE PA,et al.Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan,Cote d'Ivoire,in the ANRS 12109 TEm AAStudy,Step 2[J].Antimicrob Agents Chemother,2011,55(3):1315-1317.
|
|
[40] SIBERRY GK,JACOBSON DL,KALKWARF HJ,et al.Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy[J].Clin Infect Dis,2015,61(6):996-1003.
|
|
[41] BORTOLOTTI F,GUIDO M,BARTOLACCI S,et al.Chronic hepatitis B in children after e antigen seroclearance:final report of a 29-year longitudinal study[J].Hepatology,2006,43(3):556-562.
|
DownLoad: